P21 activated kinase 6: a promising tool for predicting small cell lung cancer diagnosis and treatment response.

ABSTRACT:

Objective

Building upon the established role of P21 Activated Kinase 6 (PAK6) in tumor progression and chemoresistance pathways, we postulate its potential as a dual-function biomarker for small cell lung cancer (SCLC). This investigation aims to conduct a comprehensive evaluation of PAK6's diagnostic validity and prognostic significance through comparative analysis of PAK6 serological levels across distinct clinical cohorts to determine diagnostic thresholds, and its clinical correlation with therapeutic responsiveness.

Patients and methods

This study included 109 patients diagnosed with SCLC, 92 patients with non-small cell lung cancer (NSCLC), 85 patients with pulmonary nodules (PN), and 94 healthy individuals undergoing routine physical examinations as the normal control

SUBMITTER: Chen S 

PROVIDER: S-EPMC12288745 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature